about
Cytotoxic and targeted therapy for hereditary cancersBiomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and othersRole of Deficient Mismatch Repair in the Personalized Management of Colorectal CancerRetinal mitochondrial DNA mismatch repair in the development of diabetic retinopathy, and its continued progression after termination of hyperglycemia.A Novel Chemotherapeutic Agent to Treat Tumors with DNA Mismatch Repair DeficienciesGenetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancerTGFBR2-dependent alterations of exosomal cargo and functions in DNA mismatch repair-deficient HCT116 colorectal cancer cells.Clinical significance of microsatellite instability in colorectal cancer.Genetics, biomarkers, hereditary cancer syndrome diagnosis, heterogeneity and treatment: a review.Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicineInsights into the involvement of noncoding RNAs in 5-fluorouracil drug resistance.Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases.Fusobacterium's link to colorectal neoplasia sequenced: A systematic review and future insights.Immune Checkpoint Blockade in Breast Cancer Therapy.Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.Advantage of HSP110 (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients.Gold(iii) complexes inhibit growth of cisplatin-resistant ovarian cancer in association with upregulation of proapoptotic PMS2 gene
P2860
Q26739366-5439145F-9FA0-47F4-A75B-32C496541B53Q28072468-E37E186E-44C2-42AE-BEC7-BE68E96B9DCCQ28080176-54F6ADE6-CA43-44BD-88E3-7E4BB2EFB580Q34433611-1E4F221F-08AE-46D4-A54E-9D8B67D12C52Q37276892-CCE91D90-4270-47DD-859C-12266C95E255Q37578728-E8081B5B-342C-4139-AB13-0FE31342E929Q37736897-149F2113-7DB3-4C95-BD05-DCD44AA7EAEEQ38139284-53D9827F-BD4C-423C-8273-90D6994A2C74Q38211737-CAC53CA2-F617-43D1-BA22-3AC9B24E9E81Q38645338-6E310E01-D53E-41A0-A19A-FE8207A74063Q38732716-EAC29B87-917C-49C3-8F8F-4B015CD13E97Q38734494-4A5CF7DF-BB65-4C45-8EDD-D19074AC79CEQ39334444-E8F63B81-196F-4A07-88FE-925B3745173BQ40242246-7CA0D52E-5D86-4439-9C88-78858D821566Q47718310-F3E656E3-0A53-4346-BB60-45BB42CEB932Q48556375-C95CA4B0-DA88-4194-BCEB-9D4B3761198DQ53440447-249FC4B8-4AA5-477A-9916-BF205E286B3FQ55452501-8253CAAA-B96C-405B-AADB-EB29905C8F6BQ58921526-5725B22C-B898-43F9-BD02-0E0777605686
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Chemotherapy of MMR-deficient colorectal cancer.
@en
type
label
Chemotherapy of MMR-deficient colorectal cancer.
@en
prefLabel
Chemotherapy of MMR-deficient colorectal cancer.
@en
P2860
P1433
P1476
Chemotherapy of MMR-deficient colorectal cancer.
@en
P2093
P2860
P2888
P304
P356
10.1007/S10689-013-9633-Z
P577
2013-06-01T00:00:00Z
P6179
1023037864